Bullous pemphigoid (BP)
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. BP was confirmed (positive for clinical manifestations, histology, direct immunofluorescence and anti-BP180 antibody); 2. Moderate to severe (10-50%BSA); 3. Aged 50-80 years, no gender limit; 4. Had not received immunosuppressive therapy, systemic glucocorticoid therapy or biologics in the last 3 months before screening; 5. Volunteer as a subject and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. BP patients with mainly mucosal manifestations/only mucosal involvement; 2. Combined with other skin diseases, such as psoriasis, urticaria, eczema, which can affect the judgment of curative effect; 3. Pregnant/lactating patients/patients planning to become pregnant in the near future; 4. Participate in another clinical study within the last 3 months; 5. Patients who cannot be followed up regularly; 6. Karnofsky <50 points; 7. Use drugs that interact with the drugs in the study due to other diseases; 8. Absolute contraindications for minocycline/glucocorticoid use (e.g., allergy to study drug, use of attenuated live vaccine within 1 month, combination of severe infection, severe uncontrolled hyperglycemia/hypertension, severe heart, lung, liver and renal insufficiency, etc.); 9. Tumors with malignant neoplasms (excluding non-melanoma skin cancer/carcinoma excised in situ); 10. Severe, uncontrolled mental illness/neurological disease; 11. Patients addicted to alcohol or drugs; 12. The presence of other critical illnesses or other conditions that the clinician has determined preclude participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| treatment effect;adverse reaction; | — |
Secondary
| Measure | Time frame |
|---|---|
| cumulative dose of glucocorticoids used;treatment costs; | — |
Countries
China